Psyence Biomedical Ltd.
PBM
$3.48
-$0.08-2.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 82.94% | 82.94% | 28.86% | 4.79% | 46.76% |
| Depreciation & Amortization | 8.33% | 8.33% | 30.00% | 44.44% | 1,100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.65% | 120.65% | 30.18% | 25.21% | 34.28% |
| Operating Income | -120.65% | -120.65% | -30.18% | -25.21% | -34.28% |
| Income Before Tax | -153.67% | -153.67% | -632.37% | -167.31% | 96.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -153.67% | -153.67% | -632.37% | -167.31% | 96.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.67% | -153.67% | -632.37% | -167.31% | 96.07% |
| EBIT | -120.65% | -120.65% | -30.18% | -25.21% | -34.28% |
| EBITDA | -120.81% | -120.81% | -30.17% | -25.19% | -34.09% |
| EPS Basic | 84.50% | 84.50% | -- | -- | -- |
| Normalized Basic EPS | 81.09% | 81.09% | -- | -- | -- |
| EPS Diluted | 84.49% | 84.49% | -- | -- | -- |
| Normalized Diluted EPS | 81.09% | 81.09% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,537.65% | 1,537.65% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,537.65% | 1,537.65% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |